Respi Points

See how RespiPoints can benefit
your patients

Encourage them to sign up at

JoinRespiPoints.com

The ability to improve adherence right
from the start

Patients enrolled in this free program, exclusive to Boehringer Ingelheim, receive incentives so they are more involved in their daily treatment.

Patients refill their prescriptions
more frequently1

85%

Reduction in days
Between Refills

10.9 days before RespiPoints vs 1.6 days after RespiPoints.

And stay on therapy longer1

3.7

Additional refills
over 12 months

survey design:

SURVEY DESIGN: Results from a 2017, 9-month, branded pilot program, with 2319 patients in the US. The HealthPrize platform provided patients with customized education, healthy habits, and a way to track daily medication adherence, as well as verifying monthly refills.1

Prescribe knowing there's coverage and savings for eligible patients*

STIOLTO RESPIMAT Savings Card

Patients may also be eligible to pay as little as $0 with the STIOLTO RESPIMAT Savings Card. Call 1‑877‑498‑7429 with any questions.

Flag your patients for STIOLTO RESPIMAT knowing there's Medicare coverage:

  • As a reminder, typically dual-eligible patients have no co-pay under Medicare Part D

*Please see Terms and Conditions here. Medicare/Medicaid/cash-paying patients excluded from Savings Card enrollment.
Patients requiring further assistance can access benefits through the patient assistance program, BI Cares, at BIPatientAssistance.com.

Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 08/01/2018.

Placement on formulary does not establish clinical comparability of products, including safety and
efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or
www.medicare.gov for most current information, as it may change without notice. This is not intended
to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. does not
sponsor or endorse any particular plan.

Request samples of STIOLTO RESPIMAT

STIOLTO Sample Box

Get your patients started, request samples of STIOLTO RESPIMAT online.

Nearly 12 million prescriptions for COPD medicines in the RESPIMAT inhaler have been written

Source: IQVIA LRx & Dx data collected from January 2013 through September 2019.

Support resources for your patients

IMPORTANT SAFETY INFORMATION
for STIOLTO RESPIMAT

CONTRAINDICATION

Use of a LABA, including STIOLTO RESPIMAT, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma.

STIOLTO is contraindicated in patients with hypersensitivity to tiotropium, ipratropium (atropine derivatives), olodaterol,
or any component of this product.

In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema
(including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also
reported in clinical trials with STIOLTO.

INDICATION for STIOLTO RESPIMAT

STIOLTO® RESPIMAT® (tiotropium bromide and
olodaterol) Inhalation Spray is a combination of tiotropium,
an anticholinergic, and olodaterol, a long-acting beta2
adrenergic agonist (LABA), indicated for the long-term,
once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic
bronchitis and/or emphysema.

Important Limitations of Use

STIOLTO is NOT indicated to treat acute deterioration
of COPD and is not indicated to treat asthma.


WARNINGS AND PRECAUTIONS

LABA as monotherapy (without an ICS), for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients,
increases the risk of asthma-related hospitalizations.

Do not initiate STIOLTO in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue
therapy for acute symptoms. Acute symptoms should be treated with an inhaled short-acting beta2‑agonist.

STIOLTO should not be used more often or at higher doses than recommended, or with other LABAs as an overdose may result.

If immediate hypersensitivity reactions occur, such as urticaria, angioedema, rash, bronchospasm, anaphylaxis, or itching, discontinue
STIOLTO at once and consider alternative treatment. Patients with a history of hypersensitivity reactions to atropine or its derivatives
should be closely monitored for similar hypersensitivity reactions to STIOLTO.

If paradoxical bronchospasm occurs, discontinue STIOLTO immediately and institute alternative therapy.

STIOLTO can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, systolic or
diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO may need to be discontinued.

Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, in patients with known or suspected
prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines.

Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms
of acute narrow-angle glaucoma develop.

Use with caution in patients with urinary retention especially in patients with prostatic hyperplasia or bladder-neck obstruction.
Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) should be monitored closely for
anticholinergic side effects.

Be alert to hypokalemia and hyperglycemia.

ADVERSE REACTIONS

The most common adverse reactions with STIOLTO (>3% incidence and higher than an active control) were: nasopharyngitis,
12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), and back pain, 3.6% (1.8%/3.4%).

DRUG INTERACTIONS

  • Use caution if administering adrenergic drugs because sympathetic effects of olodaterol may be potentiated.
  • Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol.
  • Use with caution in patients taking non–potassium-sparing diuretics, as the ECG changes and/or hypokalemia may worsen with
    concomitant beta-agonists.
  • The action of adrenergic agents on the cardiovascular system may be potentiated by monoamine oxidase inhibitors or tricyclic
    antidepressants or other drugs known to prolong the QTc interval. Therefore, STIOLTO should be used with extreme caution
    in patients being treated with these drugs. Use beta-blockers with caution as they not only block the therapeutic effects of
    beta-agonists, but may produce severe bronchospasm in patients with COPD.
  • Avoid co-administration of STIOLTO with other anticholinergic-containing drugs as this may lead to an increase in
    anticholinergic adverse effects.

STIOLTO is for oral inhalation only.

The STIOLTO cartridge is only intended for use with the STIOLTO RESPIMAT inhaler.

Inform patients not to spray STIOLTO into the eyes as this may cause blurring of vision and pupil dilation.

CL-STO-100021 6.5.2019

Please see accompanying full Prescribing Information, Patient Information, and Instructions for Use for STIOLTO RESPIMAT.

Reference: 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.